Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd VPTDF


Primary Symbol: V.VPT

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by jopatcloon Nov 13, 2024 11:03am
29 Views
Post# 36310289

RE:👀Fud Before no sales &now there been essentially no sales😉

RE:👀Fud Before no sales &now there been essentially no sales😉
jopatclo wrote: Interesting  positif the vulture GranhamB mec no shares Ventripoint . See before no sales & now  ( It will be interesting to see if they have been able to get any sales....there been essentially no sales ) 
-CardioLogic Ltd Introducing Ventripoint 4.0! Ventripoint is a groundbreaking cardiac imaging tool that converts echo images into accurate volumes and ejection fractions for all four heart chambers, delivering results with the accuracy of cardiac MRI.
With its new capabilities, Ventripoint 4.0 provides additional insights, including: 
-3D Tensors: Visualise the direction and magnitude of surface changes.
-4D Motion: Simulate a dynamic heart model across the cardiac cycle.
-3D Global Strain: Assess longitudinal, circumferential, and total surface area changes.
-3D Heat Map: Visualise surface area changes in a new heat map view.
-3D Segmentation: Access a detailed polar map for surface area change analysis.
- Now That V4.0 Europe V4.0 ok & Canada -The BEST automation and analysis of the PLANET GEN3EHO   https://ascendcv.com/ (Ventripoint - The integration of Gen3Echo with Ventripoint’s innovative application of AI to echocardiography provides tremendous value to pediatric and adult echocardiographers in caring for their most complex patients.)
- I think they know more about the Ventripoint tech than the whiners on this board. Something could happen anytime real fast!
FDA 4.0 It will happen, but not in a way we originally hoped. No investor is happy with the current outcome. You either wait or move on.
- Dr. Adams is a visionary with Ventripoint FDA V4.0 and Sales at any time now Insiders know!
https://ascendcv.com/ #vpt, and Remember
Clik integrations and see Seamless, flexible integration with heterogeneous AI, imaging and enterprise IT environments enables a best-of breed approach. Examples include:
  • Us2.ai - Benefit from the the industry’s most sophisticated integration of Us2.ai.
    • Us2.ai FDA-approved measurements feed ASE-validated suggested interpretations that can automatically complete the echo report 
    • Save time with single-click navigation to the automated measurement source frame 
    • 1-click sync to automated measurement frame
    • Distinct review processes for FDA-cleared versus investigational measurements, enhancing compliance and clarity 
    • Automatic grouping of Us2.ai measurements accelerates the measurement review process 
    • Visual notification of user edits performed on Us2.ai measurements promotes transparency and traceability 
  • Engineered for seamless integrationGen3Echo was designed with commitment to openness, seamlessly integrating with AI, ML, and advanced visualization software to foster innovation and collaboration. 
    • Ventripoint - The integration of Gen3Echo with Ventripoint’s innovative application of AI to echocardiography provides tremendous value to pediatric and adult echocardiographers in caring for their most complex patientsVentripoint’s VMS product is powered by its proprietary KBR technology and provides accurate volumetric cardiac measurements with sMRI levels of accuracy. It can be used with all ultrasound systems supported by regulatory market approvals and is seamlessly integrated into the reading workflow enhancing diagnostic precision and treatment planning, ultimately improving the quality of pediatric care.


GranhamB the vulture see Ventripoint Diagnostics Ltd.'s next-gen cardiac imaging system has been approved for use in EU and Canada (FDA reviewing). It provides more accurate cardiac output data for echo images. Automated, fast and easy to integrate into workflows.

Existing users include Duke, Sick Kids, Seattle Children's, Vienna Children's, East Midlands, Evalina and German Heart Center.
<< Previous
Bullboard Posts
Next >>